Abstract: The present invention provides sulfamate derivative prodrugs of the dopamine agonist (4aR,10aR)-1-Propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[g]quinoline-6,7-diol, their use in the treatment of conditions for which treatment with a dopamine agonist is therapeutically beneficial and pharmaceutical compositions comprising compounds of the invention. Compounds according to the invention are of formula (Id), wherein R1 and R2 are each independently selected from H, and substituent (iii) below, wherein * indicates the attachment point to oxygen, wherein R3 is selected from H and COR4, and wherein R4 is selected from H and C1-C6 alkyl, with the proviso that R1 and R2 cannot both be H,15 or a pharmaceutically acceptable salt thereof.

Abstract: The invention provides methods and material for diagnosis and treatment of ccRCC. Thus, the invention relates to a method for diagnosis or treatment of clear cell renal cell carcinoma (ccRCC) in an individual in an individual in need thereof, wherein the method comprises use of an SLC6A3 ligand linked to a radioactive label, a cytotoxic moiety or an immunomodulatory moiety.

Abstract: The present invention relates to novel compounds which are pyrazolo[1,5-a]pyrimidines, and which modulate the activity of peroxisome proliferator-activated receptors (PPAR) &agr; and/or &ggr;. The said compounds are predicted to be useful in the treatment of metabolic diseases, e.g. type II diabetes.

Abstract: The present invention relates to a method for identifying compounds capable of binding the ligand binding domain of peroxisome proliferator-activated receptor gamma (PPAR&ggr;), and selectively modulating the activity of PPAR&ggr;. The said method includes providing compounds that fit spatially and preferentially into a PPAR&ggr; ligand binding domain having the pharmacophoric features shown in Table I in the patent specification.

Abstract: The present invention relates to 2-(benzoylamino)benzoic acid derivatives of the formula I 1